The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.
BACKGROUND
Reconstitution of immune function during potent antiretroviral therapy can prompt discontinuation of maintenance cytomegalovirus (CMV) therapy but has also been associated with sight-threatening inflammatory conditions including immune recovery uveitis (IRU).


METHODS
Patients with inactive CMV retinitis and a CD4+ cell count above 100/mm3, receiving CMV therapy and stable combination antiretroviral therapy, were assigned to one of two groups based on willingness to discontinue CMV therapy.


RESULTS
Thirty-eight participants were enrolled: 28 discontinued anti-CMV therapy (Group 1) and 10 continued CMV treatment (Group 2). Median on-study follow-up was 16 months. One Group 1 participant who experienced an increase in plasma HIV viral load and a decline in CD4+ cell count developed confirmed progression of CMV retinitis. Progression or reactivation CMV retinitis was not observed among Group 2. IRU was present at study entry in 3 participants. Six participants in Group 1 and 3 participants in Group 2 developed IRU on-study. CMV viremia was not detected in any participants, and urinary shedding of CMV was intermittent.


CONCLUSIONS
Recurrence of CMV retinitis following discontinuation of anti-CMV therapy among patients with antiretroviral-induced increases in CD4+ cell count was rare. However, IRU was common in both those who maintained and discontinued anti-CMV therapy.
Wohl
D A
DA
University of North Carolina, Chapel Hill, North Carolina 27516-7215, USA. wohl@med.unc.edu
Kendall
M A
MA
Owens
S
S
Holland
G
G
Nokta
M
M
Spector
S A
SA
Schrier
R
R
Fiscus
S
S
Davis
M
M
Jacobson
M A
MA
Currier
J S
JS
Squires
K
K
Alston-Smith
B
B
Andersen
J
J
Freeman
W R
WR
Higgins
M
M
Torriani
F J
FJ
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003587:Cytomegalovirus / Q000276:immunology*; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D012008:Recurrence; D013375:Substance Withdrawal Syndrome / Q000276:immunology; D014605:Uveitis / Q000150:complications / Q000276:immunology* / Q000821:virology
D000998:Antiviral Agents; D012367:RNA, Viral